Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Henry

Showing results (561-570 of 579) with videos related to

Pageof 58
Sort By:
The Lancet. Neurology|September 20, 2025
2024 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI for the diagnosis of multiple sclerosisFrederik Barkhof, Daniel S Reich, Jiwon Oh, et al.
Neurology|September 2, 2025
Frequency and Diagnostic Implications of Paramagnetic Rim Lesions in People Presenting for Diagnosis to a Multiple Sclerosis ClinicBrian Renner, Elizabeth Daphne Verter, Martina Absinta, et al.
Science Translational Medicine|April 24, 2020
LRRK2 inhibitors induce reversible changes in nonhuman primate lungs without measurable pulmonary deficitsMarco A S Baptista, Kalpana Merchant, Ted Barrett, et al.
The Journal of Experimental Medicine|February 28, 2022
Molecular architecture determines brain delivery of a transferrin receptor-targeted lysosomal enzymeAnnie Arguello, Cathal S Mahon, Meredith E K Calvert, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|November 28, 2023
The Genetic Drivers of Juvenile, Young, and Early-Onset Parkinson's Disease in IndiaShan V Andrews, Prashanth L Kukkle, Ramesh Menon, et al.
Annals of Neurology|December 8, 2021
Spinal Cord Atrophy Predicts Progressive Disease in Relapsing Multiple SclerosisAntje Bischof, Nico Papinutto, Anisha Keshavan, et al.
Annals of Neurology|March 2, 2022
Reply to "Spinal Cord Atrophy Is a Preclinical Marker of Progressive MS"Antje Bischof, Nico Papinutto, Anisha Keshavan, et al.
Science Translational Medicine|June 8, 2022
Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson's diseaseDanna Jennings, Sarah Huntwork-Rodriguez, Anastasia G Henry, et al.
AJNR. American Journal of Neuroradiology|September 27, 2024
Multicenter Automated Central Vein Sign Detection Performs as Well as Manual Assessment for the Diagnosis of Multiple SclerosisA R Manning, V Letchuman, M L Martin, et al.
Biorxiv : the Preprint Server for Biology|October 1, 2025
A Common PD-Risk <i>GBA1</i> Variant Disrupts LIMP2 Interaction, Impairs Glucocerebrosidase Function, and Drives Lysosomal and Mitochondrial DysfunctionOliver B Davis, Jennifer E Kung, Sonnet S Davis, et al.
Pageof 58

Showing results (561-570 of 579) with videos related to

Sort By:
Pageof 58
The Lancet. Neurology|September 20, 2025
2024 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI for the diagnosis of multiple sclerosisFrederik Barkhof, Daniel S Reich, Jiwon Oh, et al.
Neurology|September 2, 2025
Frequency and Diagnostic Implications of Paramagnetic Rim Lesions in People Presenting for Diagnosis to a Multiple Sclerosis ClinicBrian Renner, Elizabeth Daphne Verter, Martina Absinta, et al.
Science Translational Medicine|April 24, 2020
LRRK2 inhibitors induce reversible changes in nonhuman primate lungs without measurable pulmonary deficitsMarco A S Baptista, Kalpana Merchant, Ted Barrett, et al.
The Journal of Experimental Medicine|February 28, 2022
Molecular architecture determines brain delivery of a transferrin receptor-targeted lysosomal enzymeAnnie Arguello, Cathal S Mahon, Meredith E K Calvert, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|November 28, 2023
The Genetic Drivers of Juvenile, Young, and Early-Onset Parkinson's Disease in IndiaShan V Andrews, Prashanth L Kukkle, Ramesh Menon, et al.
Annals of Neurology|December 8, 2021
Spinal Cord Atrophy Predicts Progressive Disease in Relapsing Multiple SclerosisAntje Bischof, Nico Papinutto, Anisha Keshavan, et al.
Annals of Neurology|March 2, 2022
Reply to "Spinal Cord Atrophy Is a Preclinical Marker of Progressive MS"Antje Bischof, Nico Papinutto, Anisha Keshavan, et al.
Science Translational Medicine|June 8, 2022
Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson's diseaseDanna Jennings, Sarah Huntwork-Rodriguez, Anastasia G Henry, et al.
AJNR. American Journal of Neuroradiology|September 27, 2024
Multicenter Automated Central Vein Sign Detection Performs as Well as Manual Assessment for the Diagnosis of Multiple SclerosisA R Manning, V Letchuman, M L Martin, et al.
Biorxiv : the Preprint Server for Biology|October 1, 2025
A Common PD-Risk <i>GBA1</i> Variant Disrupts LIMP2 Interaction, Impairs Glucocerebrosidase Function, and Drives Lysosomal and Mitochondrial DysfunctionOliver B Davis, Jennifer E Kung, Sonnet S Davis, et al.
Pageof 58